Lindi Chen

发表

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse

S. Cohn, G. Schleiermacher, N. Bown, 2016, Oncotarget.

Meeting report—3rd Neuroblastoma Research Symposium, Liverpool, 6–7th November, 2013

G. Blanchard, E. Bell, V. Viprey, 2014, Pediatric blood & cancer.

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.

G. Perini, D. Newell, L. Evans, 2015, Cancer letters.

Predicting prognosis and immune responses in hepatocellular carcinoma based on N7-methylguanosine-related long noncoding RNAs

Lindi Chen, Yiren Gao, Hongxuan Wu, 2022, Frontiers in Genetics.

Distribution characteristics of terrestrial and marine lipid biomarkers in surface sediment and their implication for the provenance and palaeoceanographic application in the northern South China Sea

G. Jia, Juan He, Li Li, 2022, Marine Geology.

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells

N. Curtin, D. Harrison, H. Bryant, 2021, Cancers.

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms

N. Curtin, D. Tweddle, Lindi Chen, 2020, Cancers.

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

J. Lunec, D. Newell, S. Middleton, 2015, Oncotarget.

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

N. Curtin, D. Tweddle, Lindi Chen, 2020, Frontiers in Oncology.

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

P. Gestraud, D. Surdez, O. Delattre, 2022, bioRxiv.

THE ROLE OF MYCN IN CHILDHOOD CANCERS

G. Blanchard, E. Bell, Lindi Chen, 2014 .

p53 is Nuclear and Functional in Both Undifferentiated and Differentiated Neuroblastoma

M. Cole, J. Lunec, K. Wood, 2007, Cell cycle.

MYCN oncoprotein targets and their therapeutic potential.

J. Lunec, E. Bell, G. Marshall, 2010, Cancer letters.

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance

D. Tweddle, Lindi Chen, 2012, Front. Oncol..

Neuroblastoma and the p53 Pathway

D. Tweddle, Lindi Chen, 2015 .

p53 is a direct transcriptional target of MYCN in neuroblastoma.

Nunzio Iraci, J. Lunec, G. Perini, 2010, Cancer research.

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

J. Lunec, Yan Zhao, D. Newell, 2019, International journal of cancer.

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.

J. Lunec, M. Hogarty, D. Tweddle, 2018, International journal of oncology.

Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers

D. Jamieson, S. Burchill, D. Murphy, 2019, Clinical Cancer Research.

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma

J. Lunec, Yan Zhao, D. Newell, 2014, British Journal of Cancer.

Newcastle University E-prints Citation for Item: P53, Skp2, and Dkk3 as Mycn Target Genes and Their Potential Therapeutic Significance

D. Tweddle, Lindi Chen, Robinson Library, 2022 .